For instance, lower levels may play a role in many conditions that are more likely to develop in older people
Eur J Biochem 50:305315 Nicholls DG, Ferguson SJ (2002) Bioenergetics 3, Academic Press, an imprint of Elsevier Science
doi:10.1097/JCP.0000000000000210 105 Bloch, M
The I-TASSER Suite: protein structure and function prediction
Before the company applied to the FDA for the drug to be approved for obesity, Knudsen and her colleagues 'developed a new methodology to show how [GLP-1] drugs exert their effect on the brain by working on the circumventricular organs and communicating further into the hypothalamus, among other effects.' This was designed to illustrate how GLP-1 worked in 'well- defined neurons in the hypothalamus, in the hindbrain, and in the reward centers.' Their rationale for developing the method was because 'It was very important to show that these medicines work on defined brain circuits and not ones that may be related to psychiatric or cardiovascular side effects, for example' (Nair
